obligations may

Instruction 1(b)

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasnington,	D.C.	20548

STATEMENT C

OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bradway Robert A</u>					2. Issuer Name and Ticker or Trading Symbol AMGEN INC [AMGN]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
				1	<u>,10</u>	<u> </u>	L 2	iwor.	J					X	Direc	tor		10% C	wner	
(Last)	(Fi	(First) (Middle)				Date of Earliest Transaction (Month/Day/Year)									X		Officer (give title elow)		Other below)	(specify
ONE AMGEN CENTER DRIVE				03/	03/05/2014									Chairman, CEO and President						
(Street) THOUSAND CA 91320-1799 OAKS				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
															Form filed by More than One Reporting Person					
(City)	(St	ate) (2	Zip)																	
		Tabl	e I - Nor	n-Deriv	ative	Se	curitie	s Acc	quired,	Dis	posed o	f, o	r Ben	eficia	ally (Owne	ed			
1. Title of Security (Instr. 3) 2. Transa Date (Month/L				Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)				ities Acquired (A) d Of (D) (Instr. 3,			4 and S		Securities Beneficially		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				(111501.4)
Common Stock 03/0					5/2014				A		51,534		A	\$	0	220,439(1)(2)]	D	
		Та	ıble II - I								sed of, onvertib				y Ov	vned				
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security Security 2. Conversion Date (Month/Day/Year) (Month/Day/Year) 3A. Deemed Execution Date (Month/Day/Year) (Month/Day/Year)		Date,	4. Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date E: Expiratio (Month/D	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amour or Numbe of		ount	Deriv	rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					

Explanation of Responses:

/s/ Andrea A. Robinson, Attorney-in-Fact for Mr.

03/07/2014

Bradway

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 4,500 RSUs which fully vest on 4/26/2014; 14,070 RSUs which vest in one installment of 6,930 on 4/25/2014 and one installment of 7,140 on 4/25/2015; 20,938 RSUs which vest in three installments of 6,909, 6,910 and 7,119 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 18,693 RSUs which vest in three installments of 6,168, 6,169 and 6,356 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively; and 15,132 RSUs which vest in three installments of 4,993, 4,994 and 5,145 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis

^{2.} These shares include 1,016 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.